Treadmill testing is used to estimate the severity of claudication, but routine use is not practical or cost-effective in all settings. Thus, the purposes of this study were: (1) to develop and cross-validate prediction equations for treadmill claudication pain distances in a heterogeneous cohort of peripheral arterial occlusive disease patients, and (2) to determine if the regression equations were more accurate in assessing claudication distances than self-reported distances of patients. Medical history, vital signs, resting ankle/brachial systolic pressure index (ABI), and claudication distances during a graded treadmill test were obtained on a validation group of 178 claudicants and on a cross-validation group of 94 c1audicants. The independent predictors of claudication pain distances of the validation group were ABI, body mass index, gender, and current smoking status, with multiple correlation coefficients of R=0.73 and R=0.82 for the distances to onset and to maximal pain, respectively. These equations were successfully cross-validated on an independent group of claudicants, as the predicted distances to onset of claudication pain (167.2±102.6 m) and to maximal pain (354.6±154.3 m) were similar (p=0.99) to measured distances (169.1±127.8 m and 356.6±181.0 m, respectively). However, the selfreported distances to onset (89.5±126.3) and to maximal claudication pain (189.2±284.3) were 1-2 blocks less than either the measured or predicted distances (p<O.Ol). It is concluded that claudication pain distances during an incremental treadmill test can be more accurately estimated from a composite of variables obtained during medical screening than by relying on the self-report of patients. Consequently, in clinical settings where treadmill testing is impractical, the functional severity of claudication can be assessed without exercise testing.
Introduction
Treadmill testing is used to elicit claudication pain and to determine the functional severity of peripheral arterial occlusive disease (PAOD).I-6 However, routine use of treadmill exercises is not feasible, practical, or cost-effective in all clinical settings." Under these circumstances, estimates of claudication pain distances may be an alternative to assess the functional limitations imposed by PAOD without having to measure the actual distances during a treadmill test.
In previous studies, the use of either self-reported claudication distances or questionnaires have been the methods used to estimate the functional severity of PAOD.8-11 Selfreported distances are inaccurate, however, as they correlate poorly with actual measured distances.v? Problems also exist with a well-established questionnaire for claudication,'? as it is used to determine whether or not claudication symptoms exist, but it does not adequately assess the severity of disease. A recently developed questionnaire An alternative to the self-report or questionnaire methods is to use the technique of multiple regression to predict the claudication distances or times of treadmill walking from a battery of objective, resting non-invasive measurements and medical history data routinely obtained from PAOD patients. A previous study found that measurements of resting anklelbrachial systolic pressure index (ABI), laterality of PAOD (unilateral versus bilateral claudication pain symptoms), and gender of the patient were the three most important independent predictors of treadmill claudication distances." Specifically, long distances to onset and to maximal pain were found in men, in patients with unilateral claudication, and in patients with high resting ABI values. Furthermore, these three-variable regression equations yielded higher correlations with treadmill claudication distances'? than compared to self-report''" and questionnaire!' methods.
Although the multiple regression equations show promise for predicting the functional severity of PAOD. they were developed on a relatively small homogeneous sample of carefully screened caucasian, nondiabetic patients who were not on anticoagulant therapy. Consequently, these regression equations may not be generalizable to a more heterogeneous sample of claudicants.
Thus, the purposes of this study were: (1) to develop and cross-validate prediction equations for treadmill claudication pain distances in a heterogeneous cohort of PAOD patients; (2) to determine if the regression equations were more accurate in assessing claudication distances than selfreported distances of patients.
Methods

Selection of patients
A total of 272 out of 313 consecutive PAOD patients with stable claudication symptoms qualified for this study. Two hundred and sixty-one patients were referred from vascular clinics, while the remaining 52 patients were recruited from the community with newspaper advertisements. Patients in the validation group (n=178) were tested at Arizona State University, the Arizona Heart Institute, and the University of Vermont between 1987 and 1993. Patients in the crossvalidation group (n=94) were tested at the Baltimore Veterans Affairs Medical Center between 1994 and 1995. The inclusion criterion for entry into the study was a history of claudication pain secondary to PAOD. Claudicants were excluded for the following medical conditions: (I) leg pain while at rest, (2) ST-segment depression greater than 2 mm at rest, (3) exercise tolerance limited by factors other than claudication (e.g. dyspnea, fatigue, dizziness, arthritis), (4) exercise-induced leg pain not of cardiovascular origin (determined from hemodynamic measurements of the symptomatic legs during and following exercise, and from the verbal description of the pain response). These criteria have been used in previous investigations.v<P:'? Patients who were current smokers refrained from smoking on the day of testing until the procedures were completed, determined by self-report. The procedures used in this study were approved by the institutional review boards for research involving humans. Written informed consent was obtained from each patient prior to investigation.
Measurements obtained during supine rest
Hemodynamic Patients rested supine for 20 min, after which ankle systolic blood pressure, brachial systolic and diastolic pressures, and heart rate measurements were recorded, and ABI was calculated. Ankle systolic pressure was measured with a Versatone bidirectional Doppler (Model 0-9) and bidirectional probe (Model P-92; 8 MHz) in the posterior tibial and dorsalis pedis arteries of both legs. The higher of the two arterial pressures from the more severely diseased leg was recorded as the resting ankle systolic pressure. Brachial systolic and diastolic blood pressures were taken from both arms by the auscultatory method. The arm yielding the higher systolic pressure was used to calculate the resting ABI. The measurement and calibration procedures have been previously described in detail. 2 The age, weight, height, body mass index (ABI; weight/height") and hemodynamic measurements of the validation and cross-validation groups are shown in Table I .
Medical history
A medical history form was also completed during the 20 min of supine rest. Gender, race, previous PAOD-related Vascular Medicine 1996; 1: 91-96 operations, claudication pain symptoms in either one or both legs, previous and current smoking habits, current use of beta-blockade medication, presence of diabetes, duration of symptoms, and the self-reported walking distance in onehalf block intervals (1 block = 300 feet) 1 I which elicited onset and maximal claudication pain were recorded. The medical history data were coded in the following format: gender (I =male, 2=female), race (1=Caucasian, 2=African-American), prior PAOD operation including either percutaneous transluminal angioplasty or bypass procedures (1=no, 2=yes), laterality of claudication pain (1=unilateral, 2=bilateral), location of lesions (1=distal, 2=proximal, 3=proximal and distal) determined from segmental leg pressures, current smoking status (1=no, 2=yes), current use of beta-blockers O=no, 2=yes), presence of diabetes (1=no, 2=yes), and duration of symptoms. The medical history data are displayed in Table 2 .
Exercise test procedures and claudication pain measurements
Following 20 min of supine rest, patients performed a progressive graded treadmill protocol (2 mph, 0% grade with 2% increase every 2 min) and indicated when the onset and maximal claudication pain levels occurred. A pain scale ranging from 0 to 4 (O=no pain, l=onset of pain, 2=moderate pain, 3=intense pain, 4=maximal pain) was used to assist the patients in identifying their degree of pain during and following the exercise test. 14 The distances (rn) walked from the start of exercise to the onset of claudication pain and to maximal pain were calculated by multiplying the speed of the treadmill (m/sec) by the time to the pain occurrences (sec). Exercise was discontinued upon attainment of maximal claudication pain. This testing protocol has yielded reliable measurements in previous investigations.F'
Statistical analyses
Validation of regression equations Unpaired z-tests were done to determine whether the validation and cross-validation groups had similar baseline characteristics. Using the validation group, stepwise multiple regression was performed to determine the factors independently related to the walking distances to the onset and to maximal claudication pain during a graded treadmill test."
Cross-validation of regression equations
To cross-validate both regression equations, they were applied to a prospective group of patients (cross-validation group) and their accuracy was assessed in the following four ways. First, the measured and predicted means for the onset and maximal pain distances were compared using paired r-tests. Secondly, the correlation coefficients (r) between the predicted and measured claudication pain distances in the cross-validation group were statistically compared with the multiple correlation coefficients (R) obtained from the regression equations using the validation group by an independent z-test." Thirdly, the total error in the prediction was calculated.F:" Fourthly, the coefficient of variation between the measured and predicted claudication distances was calculated to determine the individual variability associated with the prediction equations. These above statistical procedures have been recommended .n crossvalidation procedures" and have been used in several other studies. [19] [20] [21] [22] Comparison of measured. predicted. and self-reported claudication distances Paired r-tests were performed to assess whether the measured claudication distances were different from the predicted distances and from the self-reported claudication distances. Pearson product-moment correlation coefficients (r)
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Results
Comparison of the validation and cross-validation groups
The baseline characteristics of the claudicants in the validation and cross validation groups are displayed in Tables I  and 2 . All values were similar between the two groups.
Regression equation developed on the validation group
The independent predictors of the distance to onset of claudication pain and the distance to maximal pain were ABI, BMI, gender, and current smoking status (Tables 3  and 4 ). The multiple correlation coefficients between these four variables and the distances to onset and to maximal claudication pain were R=O.73 and R=O.82, respectively. Resting ABI was the most important predictor, as patients with higher ABI values had longer claudication pain distances. The BMI was the second most important predictor, as patients who had lower BMI values (i.e. lower weight relative to their height) had longer claudication. pain distances independent of ABI. Gender was the third most important predictor, as men had longer walking distances to onset and to maximal claudication pain than women independent of resting ABI and BMI. Current smoking status was the final predictor, as nonsmokers had longer walking distances than smokers, independent of ABI, BMI and gender. The distances to onset and to maximal claudi- 
Discussion
*Significantly different than the measured and predicted distances (p<0.01).
predicted and measured distances (r=O.68 for onset of pain; r=O.76 for maximal pain). 
Interpretation of the regression equations
Resting ABI was the strongest predictor of the distances to onset (r=O.4l) and to maximal claudication pain (r=O.5l) during the graded treadmill test. as patients with lower resting ABI values had shorter distances to onset and to maximal pain than patients with higher resting ABI. These results compare favorably with an earlier study'? which found a correlation of r=O.57 and r=O.62 between resting ABI and the distances to onset and maximal pain, respectively. in 56 claudicants who were tested using the same treadmill protocol as in this study. Similarly. Yao et al 23 demonstrated a correlation of r=O.45 between maximal pain distance and ABI in 162 claudicants who walked at 4 kmlh (2.5 mph) with no grade. A higher relationship may have been obtained in the latter study. however. if many of the patients had been allowed to continue to walk beyond 5 min. Other studies have noted a lower correlation between the maximal pain distance and resting ABP·7. 24 The BMI of patients was the second predictor of claudication distances. and this relationship was independent of resting ABI. Consequently, the added burden of carrying additional weight during graded treadmill walking hastens the development of claudication pain regardless of the severity of peripheral arterial occlusive disease. This finding suggests that intervention strategies designed to reduce body fat may have an important influence on improving the walking ability of claudicants without any alteration in the peripheral circulation.
In support of previous results," gender was the third
The main findings ofthis investigation were that: (l) ABI, BMI. gender. and current smoking status were independent predictors of the distance to onset of claudication pain and the distance to maximal pain, (2) the regression equations for predicting the distances to onset and to maximal claudication pain were successfully cross-validated on an independent group of similar PAOD patients, and (3) use of the regression equations to predict the measured claudication pain distances were more accurate than compared to the self-report method. The predicted claudication distances (m) can be converted to times (sec) by multiplying the distances by 0.896 (2 mph=O.896 m/sec).
Cross-validation analyses
Both regression equations were then applied to the crossvalidation group (n=94 (p=O.560) in the cross-validation group. Furthermore. the correlation coefficient between the measured and predicted values for the distances to onset and to maximal claudication pain in the cross-validation group were r=O.68 and r=O.76. respectively. which approximated the multiple correlation coefficients of R=O.73 and R=O.82 obtained from the regression equations generated on the validation group. This indicates that the regression equations were robust to sample-specific variation in the measured variables. The standard error of estimate associated with the distances to onset and to maximal claudication pain were 56.0 and 75.3 m, respectively, indicating that the standard deviation of the prediction of the two walking distances is within 56-75 m. The total error associated with these equations was 56.3 and 75.6 m, To determine the individual variability associated with the prediction of the walking distances, the coefficient of variation between the measured and predicted distances for each patient was calculated and then averaged across all patients. The coefficient of variation was 23.0% and 17.8% for the distances to onset and to maximal claudication pain. respectively.
Comparison of measured, predicted, and self-reported claudication distances
The claudication pain distances measured during a treadmill test. predicted by multiple regression equations. and estimated by self-report. are shown in Table 5 . The predicted claudication distances to onset and to maximal pain were only 1.9 and 2.0 m lower than the measured distances. However. the self-reported distances to onset and to maximal claudication pain were 79.6 m (approximately 1 block) and 167.4 m (approximately 2 blocks) less than the measured distances (p<0.01). Furthermore. the relationships between the self-reported distances and the measured distances (r=O.20 for onset of pain; r=O.23 for maximal pain) were weaker (p<0.0l) than the relationships between the most important independent predictor of the treadmill claudication pain distances, as women had shorter distances compared to men. It is important to note that the more rapid development of claudication pain in women was not due to lower resting ABI values or higher BMI values. Resting ABI and BMI had already entered into the regression equations and, consequently, served as covariates of claudication pain during the subsequent steps in the analyses. These data suggest that gender characterizes a unique aspect of walking tolerance of claudication patients that is independent of resting ABI and BMI.
Smoking status was the final independent predictor of the claudication pain distances after resting ABI, BMI, and gender were taken into account. Patients who currently smoked performed worse on the treadmill test, as the distances to onset and to maximal pain occurred sooner than for their nonsmoking counterparts. Because smoking was not permitted on the day of testing, it is unlikely that the shorter claudication distances in the smokers was due to an acute effect of cigarette smoking. In fact, acute smoking appears to have either no effect or a positive effect on subsequent walking performance." Furthermore, the poorer walking ability of smokers can not be explained by differences in resting ABI, gender, or body fatness when compared to nonsmoking patients, as these variables were already entered into the regression equation.
The earlier development of claudication pain may have been due to the chronic influence of cigarette smoking on the vascular system. It may be speculated that smokers either have worse perfusion in the leg musculature, impaired pulmonary gas exchange, or both compared to nonsmokers. In either case, smokers would have a lower oxygen delivery to the exercising leg musculature. A recent study supports the notion of a lower oxygen delivery, as lower transcutaneous oxygen levels were found in the limbs of smokers."
In support of other reports, beta-blocking agents did not have an independent effect on claudication distances.Fr" Furthermore, a recent meta-analysis on 11 randomized controlled clinical trials demonstrated that beta-adrenergic blocker therapy did not worsen claudication distances or peak calf blood flow in patients with intermittent claudication." These studies, coupled with the results from the present investigation, should dispel the notion that betablockers have a negative impact on claudication distances and peripheral circulation in patients with moderately severe PAOD.
Clinical significance of predicting claudication pain
In some clinical settings treadmill tests cannot be routinely performed to evaluate claudication pain because of the equipment, personnel, and time required for such procedures. Consequently, in large epidemiologic studies, estimates of claudication pain responses rather than actual measured responses may be preferred to assess the functionallimitations imposed by PAOD. Treadmill testing may also be inappropriate for some claudication patients who have concomitant medical problems that are contraindicated for exercise, such as ECG irregularities, myocardial ischemia, angina, dyspnea, hypertension, and unsteadiness while walking.
In these situations the prediction of claudication distances from the derived regression equations may serve as
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Walking distances in arterial occlusive disease 95 a viable option for clinicians to use to assess the functional limitations imposed by claudication and its possible impact on the performance of routine daily activities. The standard deviation associated with the prediction equations, expressed as the standard error of estimate, was only 56 and 75 m for the distances to onset and to maximal claudication pain, respectively. This accuracy of predicting the pain distances within 0.5-0.75 blocks is better than relying on the self-reported claudication distances given by patients which were underestimated by 1-2 blocks. This study confirms the results of other reports that the self-report method does not correlate well with actual measured walking distances in the laboratory.v? limiting its usefulness in settings where claudication pain responses need to be estimated.
The findings in the present study suggest that the prediction of claudication pain can be enhanced substantially from the results of previous studies5.7.23.24 by simply recording gender, height, weight, and smoking status in addition to measuring resting ABI. This information will provide clinicians with a quick estimate of the functional severity of PAOD that is within 56-75 m of actually measuring the claudication distances.
Caveats to the regression equations
Although the regression equations can be used to predict the distances to onset and to maximal claudication pain, there are limitations which need to be recognized. First, the equations should not be used as a substitute for actually measuring the distances in patients who are eligible to undergo treadmill testing. Secondly, the regression equations were developed on PAOD patients under baseline conditions, and thus should only be applied to patients who have not undergone treatment for intermittent claudication (e.g. exercise rehabilitation, drug therapy, angioplasty, surgery). Application of the equations to patients following an intervention may lead to a substantial increase in the error associated with estimating claudication distances. Thirdly, the equations will work best when applied to a group of claudicants who have similar ABI, BMI, gender, and smoking profiles to that of the present group of patients. Fourthly, because the standard deviation and range of the predicted values were smaller than the measured distances, the equations will tend to be less accurate in patients at the extreme ends of the measurements. For example, in patients who are severely diseased and obese the equations will tend to overestimate the claudication distances, while an underestimate is likely to occur in patients who are mildly diseased and thin.
Summary and conclusion
In summary, this investigation found that: (I) ABI, BMI, gender, and current smoking status were independent predictors of the distance to onset of claudication pain and the distance to maximal pain, (2) the regression equations for predicting the distances to onset and to maximal claudication pain were successfully cross-validated on an independent group of similar PAOD patients, and (3) use of the regression equations to predict the measured claudication pain distances were more accurate than compared to the self-report method.
It is concluded that claudication pain distances during an incremental treadmill test can be more accurately estimated from a composite of variables easily obtained during medica! screening than by relying on the self-report of patients. Consequently, in clinical settings where treadmill testing is impractical, the functional severity of claudication can be assessed without exercise testing.
